Compare H2O America (HTO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Sana Biotechnology Inc — how do they compare? H2O America trades at $63.93 (market cap $2.70B), while Sana Biotechnology Inc trades at $3.2 (market cap $873.84M). The key difference: H2O America is far larger — about 3.1× Sana Biotechnology Inc's market cap, and H2O America pays a 2.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HTO | SANA | |
|---|---|---|
Market Cap | $2.70B | $873.84M |
Sector | Technology | Health |
52-Week High | $65.43 | $5.92 |
52-Week Low | $44.44 | $2.68 |
Enterprise Value | $4.42B | $848.03M |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $64.52, down 1.39% today, with strong technical indicators showing a bullish trend. The company maintains solid fundamentals with 12.87% net income margin and consistent earnings beats in recent quarters. Recent news highlights upcoming Q2 2026 earnings report on July 27, 2026, and institutional buying activity. Technical analysis shows support at $62-$64 with resistance at $65-$66 levels.
HTO presents a balanced investment case with 80% analyst buy ratings and a $63.50 consensus target. The water utility's stable revenue streams and dividend yield provide defensive characteristics, though valuation multiples appear full and RSI levels suggest near-term overbought conditions. Execution on $2.7 billion capex plan remains key for growth.
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
